These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21229647)

  • 1. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
    Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE
    J BUON; 2010; 15(4):791-3. PubMed ID: 21229647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
    Vincenzi B; Badalamenti G; Armento G; Silletta M; Spalato Ceruso M; Catania G; Napolitano A; Maltese G; Valeri S; Incorvaia L; Santini D; Tonini G
    Oncology; 2018; 95(1):1-7. PubMed ID: 29510410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
    Schöffski P; Dumez H; Wolter P; Stefan C; Wozniak A; Jimeno J; Van Oosterom AT
    Expert Opin Pharmacother; 2008 Jun; 9(9):1609-18. PubMed ID: 18518789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trabectedin in soft tissue sarcomas.
    Petek BJ; Loggers ET; Pollack SM; Jones RL
    Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Grignani G; Martín-Broto J; Schuler M; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):15-24. PubMed ID: 26043311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Going further in the knowledge of Yondelis®; what's new in clinical trials?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s7-s12. PubMed ID: 25048046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
    Le Cesne A; Domont J; Cioffi A; Bonvalot S; Terrier P; Ray-Coquard I; Alfaro V; Lebedinsky C; Santabarbara P; Blay JY
    Drugs Today (Barc); 2009 Jun; 45(6):403-21. PubMed ID: 19649331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
    Blay JY
    Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
    Le Cesne A; Reichardt P
    Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
    Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
    Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
    Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
    Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
    Le Cesne A
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
    Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
    Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
    Martin-Liberal J; Judson I
    Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin for the management of soft-tissue sarcoma.
    Boudou L; Baconnier M; Blay JY; Lombard-Bohas C; Cassier PA
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):727-37. PubMed ID: 19496709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
    Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
    Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.